Avian CpG DNA Adjuvant with Poly-G Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional adjuvants in avian vaccines, such as aluminum hydroxide gel and oil adjuvants, fail to enhance specific Th1 cell immune responses and stimulate inadequate innate and adaptive immune responses against infections, while chemically synthesized CpG ODNs are time-consuming and costly to produce, and species-specific sequences are required for effective immunostimulation.
Innovation Solution
A CpG DNA adjuvant comprising an immunostimulatory oligodeoxynucleotide with TCG tandem repeats at the 5' end, a poly-G structure at the 3' end, and avian-specific flanking sequences around the CpG motif, facilitating large-scale production and enhanced immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants (aluminum hydroxide gel, oil adjuvant) are used, then vaccine formulation is simple, but they cannot enhance specific Th1 cell immune response and stimulate inadequate innate and adaptive immune responses
Solution Approach 1:
The patent changes the chemical composition parameters of the adjuvant by incorporating CpG motifs with specific sequences (e.g., TCG tandem repeats, poly-G structure, avian-specific flanking sequences) to transform the immune response profile from inadequate to enhanced Th1 response, while maintaining manufacturability through defined molecular structures
Solution Approach 2:
The patent creates a composite adjuvant system combining CpG DNA motifs with vaccine antigens, where the CpG component (immunostimulatory oligodeoxynucleotide) works synergistically with the antigen to produce enhanced immune responses that neither component could achieve alone
2Reliability
If chemically synthesized CpG ODN is used, then immunostimulatory activity is achieved, but production is time-consuming and costly
Solution Approach 1:
The patent performs preliminary design of the CpG sequence structure (TCG repeats, poly-G, flanking sequences) to enable both immunostimulatory function and efficient production, allowing the sequence to be synthesized or produced with optimized efficiency while maintaining the required biological activity
Solution Approach 2:
The patent optimizes the sequence parameters (length, composition, specific motifs) to achieve the right balance between immunostimulatory effectiveness and production feasibility, using defined structures that can be reliably produced
3Ease of manufacture
If CpG ODN is used without PTO modification, then production is easier and cheaper, but degradation rate by DNase increases
Solution Approach 1:
The patent changes the chemical stability parameters by incorporating structural features (poly-G structure, specific sequence composition) that provide inherent resistance to DNase degradation without requiring PTO modification, maintaining production simplicity while improving stability
4Reliability
If species-specific CpG sequences are designed, then immunostimulatory effectiveness is improved, but sequence design complexity increases
Solution Approach 1:
The patent defines specific sequence parameters for avian species (TCG tandem repeats, poly-G structure, avian-specific flanking sequences) that provide reliable immunostimulation while maintaining manageable design complexity through clear structural guidelines
Solution Approach 2:
The patent applies local quality by designing specific regions of the CpG sequence with distinct functions (TCG repeats for immunostimulation, poly-G for stability, flanking sequences for species specificity), allowing each region to be optimized independently
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CpG DNA adjuvant effectively enhances avian innate and adaptive immune responses, reduces DNase digestion, and supports cellular uptake, offering improved immunostimulation compared to traditional adjuvants and chemical synthesis methods.
Implementation Method 1
Krieg A. M. et al. found that unmethylated dinucleotide CpG motifs in bacterial deoxyribonucleic acid (DNA) has advantages on stimulating several immune cells to secrete cytokines for enhancements of innate and adaptive immunity
Implementation Method 2
CpG ODN enhances DC activation, maturation and antigen-presenting function
Implementation Method 3
a poly-G structure at a 3' end... to facilitate cellular uptake of the CpG DNA adjuvant
Implementation Method 4
the phosphothioate reduces the degradation rate of the PTO-modified CpG ODN digested by deoxyribonuclease (DNase)
Data Source
AI summary
A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a sequence of SEQ ID NO: 2. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.